growth still improv fx
compens prompt cut ep
strong core growth fx crimp margin ep
revenu y/i our/street est management
provid clean core growth vs estimate fx sale vs
estimate vs estimate euroimmun double-
digit organ growth margin came well expect neg impact
fx move increas stock comp non-gaap gm
estimate adj opm estimate adj ep
vs guid street estimate
treat broad core strength anoth rais fy guid
demand broad-bas product segment custom group discoveri
analyt solut da grew organ led high-single-digit life growth
chiefli demand pharma demand appli market food
environment industri mid-singl digit diagnost dx legaci core growth
also strong dd growth immunodiagnost genom low-single-digit
reproduct health also rais organ fy guid includ
euroimmun organ contribut although smaller fx tailwind off-set
unexpect headwind increas fx stock comp stock price
strong run hit opm hit ep fx like
remain issu near term stock comp hit fade given move
far factor drove ep guid cut vs prior
updat estim stay neutral po unchang
overal solid organ quarter ep pressur like weigh
share reiter neutral rate await clariti new
growth profil beyond ie still somewhat skeptic deliv
hsd core growth adjust revenu est lower
ep estimate vs prior po stay still ep
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart waltham massachusett
found diversifi
provid scientif instrument consum
servic address basic appli
research well signific global health
safeti issu includ matern fetal health
food safeti environment monitor today
compani oper two segment
environment
diversifi provid
scientif instrument consum servic
think compani tact piec
togeth numer acquir asset sinc
form uniqu comprehens solut
custom nich market posit
portfolio transform improv
growth profil believ compani still
face near-term headwind share
like rang bound
price object base ep estim
slight premium compani broader lst diagnost peer group two
year forward multipl signific premium histor multipl
due improv core growth margin feel multipl appropri given
on-going oper improv improv growth profil compani
upsid risk po better expect organ sale growth margin
expans faster uptak new product capit deploy option
acquisit compani downsid risk competit execut integr risk
weaker macro environ fx swing fund cut slower expect
uptak new product regulatori risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
